Mergers and acquisitions

#Collaboration #Drug development #Drug discovery #Horizon Europe #Mergers and acquisitions #Partnership

New: DDW Highlights 11 September 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen the vital importance of collaboration to the… Read More

#News

#Collaboration #Drug development #Drug discovery #Horizon Europe #Mergers and acquisitions #Partnership

This week in drug discovery (4-8 September)  

News round-up for 4-8 September by DDW Digital Content Editor Diana Spencer. This week we have seen the vital importance of collaboration to the successful development and discovery of novel therapeutics, exemplified by the new deal agreed by the UK and EU to admit the UK… Read More

#News

#3D modelling #Artificial intelligence (AI) #BioPharmics #Computational chemistry #Mergers and acquisitions #Molecular Biology #Optibrium

Optibrium acquires BioPharmics

AI drug discovery company Optibrium has acquired 3D drug design specialist BioPharmics. BioPharmics’ CEO, Dr Ajay Jain, and Director of Applied Science, Dr Ann Cleves, will join the Optibrium team, respectively focusing on R&D and Application Science in the newly-created BioPharmics Division. BioPharmics has developed a series of algorithms and… Read More

#Business & Investment #News

Danaher Corporation
#Abcam #Danaher Corporation #Drug discovery #Mergers and acquisitions

Danaher to acquire Abcam

The two companies have entered an agreement in which Danaher Corporation will acquire Abcam for $24 per share in cash. The transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Founded in 1998 and headquartered in Cambridge,… Read More

#Business & Investment #News

#CorEvitas #Mergers and acquisitions #Real world data #Thermo Fisher Scientific

Thermo Fisher Scientific acquires real-world evidence provider

Thermo Fisher Scientific has completed its acquisition of CorEvitas, a provider of real-world evidence for approved medical treatments and therapies, for $912.5 million. Real-world evidence is a high growth market segment as pharmaceutical and biotechnology customers, as well as regulating bodies, are increasingly looking to monitor and evaluate the safety… Read More

#Business & Investment #News

#Business #Drug discovery #Investment #Mergers and acquisitions

Five key drug discovery deals of summer 2023

The life sciences sector has seen significant M&A activity over the last few weeks. DDW’s Diana Spencer provides an overview. BioIVT acquires PrecisionMed In July BioIVT acquired biospecimens company PrecisionMed, gaining access to, reportedly, the largest private, global repository of longitudinally collected human CSF for scientific research. “We are thrilled… Read More

#Business & Investment #Editor's Choice #News

NuChem Sciences facility
#Contract Research Organisations (CROs) #Mergers and acquisitions #NuChem Sciences #Sygnature Discovery

NuChem Sciences becomes part of the Sygnature Group

Sygnature Discovery has announced the acquisition of Canada-based contract research organisation NuChem Sciences. The transaction expands Sygnature’s business operations into the North American market. Together, Sygnature Discovery and NuChem hope to combine the best of North American and UK operations. Marc Lebel, President and Chairman at NuChem Sciences, said: “We… Read More

#Business & Investment #News

RNA
#Laboratoires Théa #Mergers and acquisitions #Ophthalmology #ProQR Therapeutics #RNA

Théa acquires ProQR’s RNA ophthalmic assets

ProQR Therapeutics and Laboratoires Théa have announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR will receive an initial payment of €12.5M and will also be eligible for up to €135M in further development, regulatory,… Read More

#Business & Investment #News

Patient receiving eye drops
#CS Pharmaceuticals #Dry eye #Mergers and acquisitions #Ophthalmology

CS acquires AxeroVision’s dry eye disease pipeline

CS Pharmaceuticals (CSP) has acquired AxeroVision, a company developing novel therapies for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes. Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270… Read More

#Business & Investment #News

Biogen head office
#ALS #Alzheimer's #Biogen #Business #Investment #Mergers and acquisitions

Biogen acquires Reata and cuts 1,000 jobs

Biogen has revealed an agreement to acquire Reata Pharmaceuticals for approximately $7.3 billion. The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. In its second quarter results, the company said… Read More

#Business & Investment #News #Trending News

#BioIVT #Biospecimen collection #Mergers and acquisitions #Neurology #Oncology #PrecisionMed

BioIVT acquires biospecimens provider PrecisionMed

BioIVT has acquired PrecisionMed, a supplier of human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics. Based in Carlsbad, CA, US, PrecisionMed has been collecting biospecimens for neurology and oncology research for more than 27 years, and reportedly has the largest private, global repository of… Read More

#Business & Investment #News

Exosomes
#AAV #Codiak Biosciences #Evox Therapeutics #Mergers and acquisitions #Preclinical development

Evox Therapeutics acquires exosome AAV technology from Codiak

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights. The technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been… Read More

#Business & Investment #News

#Compounds #eMolecules #Mergers and acquisitions #Specs

eMolecules acquires Specs Compound Handling

eMolecules has announced the acquisition of Specs Compound Handling, a provider of chemical compound management services to the life sciences industry. eMolecules provides a digital chemical search engine, specialising in unique structures with delivery options from a global network of suppliers. “Welcoming the highly reputable and talented Specs team into… Read More

#Business & Investment #News

#Antibodies #Antibody drug conjugate (ADC) #Apexigen #Mergers and acquisitions #Oncology #Pyxis Oncology

Pyxis Oncology to acquire antibody therapeutics company Apexigen

Pyxis Oncology has announced a definitive agreement by which it will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share, for a total enterprise… Read More

#Business & Investment #News

uBriGene Boston facility
#Biotech hubs #Boston #Contract development and manufacturing organisations #Mergers and acquisitions #uBriGene

Cell and gene company makes major acquisition in Boston hub

Contract development and manufacturing organisation (CDMO) uBriGene is expanding into the US market with the acquisition of a manufacturing facility from Mustang Bio. The cell & gene therapy (CGT) CDMO has an established global footprint with two GMP manufacturing facilities in China and its headquarters in Vancouver, Canada. The newly… Read More

#Business & Investment #News

#Collaboration #Drug development #Drug discovery #License agreement #Mergers and acquisitions

This week in drug discovery (8-12 May)

News round-up for 8-12 May by DDW Digital Content Editor Diana Spencer. Inspired by the relaunch of PerkinElmer’s Life Science and Diagnostics business this week as Revvity, my top five news story this week all relate to new drug discovery business developments. See below for the… Read More

#News